Pfizer’s acquisition of Metsera, announced on September 22, 2025, stands out as one of the most significant pharmaceutical deals of the year—propelling the US giant back into the race for transformational obesity drugs after earlier setbacks. The deal offers up to $7.3 billion in total potential value, including milestone-based contingent payments, and reflects a bold strategic response to shifts in both scientific opportunity and market demand.
Strategic Rationale
The global market for anti-obesity drugs is projected to exceed $150 billion within a decade, driven by innovations such as GLP-1 agonists and increasing prevalence of obesity-related health complications[1][2]. Pfizer, which recently discontinued its own oral GLP-1 candidate danuglipron over safety concerns, needed a breakthrough to re-establish its position in a market led by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy)[3][4][5].
Free Membership Required
You must be a Free member to access this content.
